Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Operating Leases: 2023-2024

Historic Operating Leases for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $1.6 million.

  • BioLineRx's Operating Leases fell 11.83% to $1.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.6 million, marking a year-over-year decrease of 11.83%. This contributed to the annual value of $1.6 million for FY2024, which is 11.83% down from last year.
  • Latest data reveals that BioLineRx reported Operating Leases of $1.6 million as of FY2024, which was down 11.83% from $1.8 million recorded in FY2023.
  • BioLineRx's 5-year Operating Leases high stood at $1.8 million for FY2023, and its period low was $1.6 million during FY2024.
  • In the last 2 years, BioLineRx's Operating Leases had a median value of $1.7 million in 2023 and averaged $1.7 million.
  • Data for BioLineRx's Operating Leases shows a maximum YoY dropped of 11.83% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows BioLineRx's Operating Leases stood at $1.8 million in 2023, then decreased by 11.83% to $1.6 million in 2024.